I received an email from the CEO, I sent a general inquiry on...

I received an email from the CEO, I sent a general inquiry on what was the plans for 2012.

This was his response.

Our plans are obviously and inevitably a function of successful capital raising and follow this basic outline:

1. complete an initial capital raise to allow the company to replace its current convertible-debt funding with new equity support; this should allow the stock price to recover (this part is reassuring).  For the past year we have been entirely dependent on our loan facility with La Jolla Cove Investors, and this remains the case now.

2. bring in a moderate follow-on raise that allows us to begin moving some of our clinical-stage product programs forward again, regaining some momentum and product progress that can drive value growth

3. follow with a third significant capital raise that will fund product development to the end of PhII clinical trials, a major value milestone and strategic value driver.